NantKwest, Inc. (NK)
Stock Price:
$9.70 USD
0.12 (1.25%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $9.76 +0.06 (0.62%) Dec 1, 7:36 PM
Key Info
| Market Cap |
1.05B |
| Revenue (ttm) |
99,000 |
| Net Income (ttm) |
-75.89M |
| Shares Out |
108.59M |
| EPS (ttm) |
-0.75 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 1 |
| Last Price |
$9.70 |
| Previous Close |
$9.58 |
| Change ($) |
0.12 |
| Change (%) |
1.25% |
| Day's Open |
9.68 |
| Day's Range |
9.47 - 10.67 |
| Day's Volume |
1,247,059 |
| 52-Week Range |
1.41 - 15.36 |
More Stats
| Market Cap |
1.05B |
| Enterprise Value |
980.91M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
108.59M |
| Float |
n/a |
| EPS (basic) |
-0.75 |
| EPS (diluted) |
-0.75 |
| FCF / Share |
-0.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.98M |
| Short Ratio |
7.11 |
| Short % of Float |
n/a |
| Beta |
2.52 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
10,639.88 |
| PB Ratio |
5.51 |
| Revenue |
99,000 |
| Operating Income |
-76.85M |
| Net Income |
-75.89M |
| Free Cash Flow |
-65.20M |
| Net Cash |
72.44M |
| Net Cash / Share |
0.67 |
| Gross Margin |
43.43% |
| Operating Margin |
-77,627.27% |
| Profit Margin |
-76,658.60% |
| FCF Margin |
-65,858.59% |
| ROA |
-28.19% |
| ROE |
-53.34% |
| ROIC |
-64.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
1 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$13.00*
(34.02% upside)
Low
8.00
Current: $9.70
High
18.00
Target: 13.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 0.04 | 0.05 | 0.05 | 0.04 | 0.24 | 0.64 | 0.60 |
| Revenue Growth | -8.51% | 4.44% | 2.27% | -81.36% | -63.18% | 6.83% | - |
| Gross Profit | 0.04 | 0.05 | 0.05 | 0.04 | 0.24 | 0.64 | 0.60 |
| Operating Income | -67.81 | -98.39 | -99.12 | -125 | -239 | -5.58 | -2.27 |
| Net Income | -65.79 | -96.23 | -96.42 | -121 | -237 | -6.19 | -2.05 |
| Shares Outstanding | 94.21 | 79.13 | 80.58 | 81.98 | 71.52 | 8.25 | 0.80 |
| Earnings Per Share | -0.70 | -1.22 | -1.20 | -1.47 | -3.31 | -0.75 | -2.57 |
| Operating Cash Flow | -61.36 | -63.38 | -48.78 | -38.59 | -25.31 | -5.42 | -0.67 |
| Capital Expenditures | -4.18 | -12.69 | -34.82 | -6.56 | -2.24 | -0.24 | - |
| Free Cash Flow | -65.54 | -76.07 | -83.60 | -45.15 | -27.55 | -5.65 | -0.67 |
| Cash & Equivalents | 51.65 | 74.87 | 128 | 199 | 294 | 59.10 | 0.35 |
| Total Debt | 10.89 | 5.95 | 1.74 | 2.03 | - | - | 1.76 |
| Net Cash / Debt | 40.77 | 68.93 | 126 | 197 | 294 | 59.10 | -1.41 |
| Assets | 143 | 182 | 250 | 317 | 367 | 60.00 | 2.10 |
| Liabilities | 22.44 | 35.94 | 31.60 | 24.08 | 10.85 | 2.41 | 5.00 |
| Book Value | 121 | 146 | 219 | 293 | 356 | 57.59 | -2.90 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
NantKwest, Inc. |
| Country |
United States |
| Employees |
160 |
| CEO |
Richard Adcock |
Stock Information
| Ticker Symbol |
NK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NK |
| IPO Date |
July 28, 2015 |
Description
NantKwest, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.